Triple threat: new combo aims to outsmart resistant colorectal cancer
NCT ID NCT07343791
First seen Jan 16, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This early-stage trial tests a combination of three treatments for people with advanced colorectal cancer who have already tried two standard therapies. The approach combines a special immune cell therapy (DC-CIK), an immunotherapy drug, and a targeted pill to attack the cancer from multiple angles. The study aims to see if this triple therapy can shrink tumors and improve survival, while monitoring safety in 14 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinling Hospital
RECRUITINGNanjing, Jiangsu, 210002, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.